Strong Revenue Growth Demonstrating Success of Company Strategy Revenue growth of 27.5% with organic revenue growth of 5.1% compared to Q1 2025Completed significant talent additions, and announced an ...
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results